On Monday Pharmaceutical companies Cipla, Sun, Lupin inked deals with US Drug-makers Eli Lilly and Co. issuing royalty-free, non-exclusive voluntary licenses to produce its baricitinib drug in India to deal with the second wave of the pandemic.
Baricitinib is an oral drug discovered by Incyte and licensed to Eli Lilly in December 2009. Typically, a patient needs 14 tablets of Baricitinib for a full-course of treatment.
Earlier, Gilead too had signed a similar deal with Indian pharmaceutical companies to expand the production much-demanded drug Remdesivir. Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Union Ministry of Health, for use of the drug in combination with Remdesivir for the treatment of the deadly disease. Eli Lilly is also in contact with many other Indian companies to expand the production of the drug.
Cipla said that the deal will provide impetus to the company’s efforts to enhance access to critical treatments for patients affected by coronavirus. It is planning to expand its leverage to make the treatment accessible for more number of people in the market. The deal will ensure high-quality manufacturing and accessibility of baricitinib improving the local treatment’s range in the market.
“Lilly is committed to supporting India in this healthcare challenge through our innovative and effective portfolio of breakthrough medicines. During the current surge, we have responded by issuing three voluntary licenses for baricitinib in India to accelerate local manufacturing and distribution under best quality condition. More licenses to additional Indian generic manufacturers are expected to be announced very soon.”
Meanwhile, India reported over 4 lakh cases in the last 24 hours in the second wave of the pandemic.